Navigation Links
Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:12/28/2009

REDWOOD CITY, Calif., Dec. 28 /PRNewswire/ -- Codexis, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold by Codexis, Inc. and certain of its stockholders.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with RBC Capital Markets Corporation and Pacific Crest Securities LLC acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, via telephone at 1-800-221-1037; or from the prospectus department of Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, New York 10004, via telephone at 1-866-471-2526 or via fax at 212-902-9316.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Codexis

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and has the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144

SOURCE Codexis, Inc.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... Annual Clinical and Scientific Meeting— OBP Medical , a ... today announced the launch of a new extra-small size ... and ER-SPEC vaginal specula. Already available in ... extra-large sizes makes OBP Medical,s line of single-use lighted ...
Breaking Medicine Technology:
(Date:5/29/2017)... CT (PRWEB) , ... May 29, 2017 , ... ... to announce a new training program for Recovery Coaches who are seeking opportunities ... emergency rooms, court systems, treatment centers, and others. Recovery Coaching and Professionalism© was ...
(Date:5/29/2017)... Pittsburgh, PA (PRWEB) , ... May 29, 2017 , ... ... seemingly simple question: How do doctors determine if someone is cured? The virus has ... the most expensive and time-consuming tests. , Scientists at the University of Pittsburgh’s Graduate ...
(Date:5/28/2017)... ... 2017 , ... Viewers likely know Rob Lowe from such 80s hits as ... his work on NBC’s The West Wing and Parks and Recreation. But recently, Lowe’s ... which puts the spotlight on important modern-day issues that face today’s society. One of ...
(Date:5/27/2017)... ... ... Most us are familiar with the sound of occasional popping joints that ... shows that certain people who experience consistent joint popping, grating and grinding are ... opportunity to treat patients before the problem becomes pronounced, potentially hedging off more severe ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® ... Algovita SCS System has been FDA approved as a treatment option for chronic intractable ... the most powerful SCS system and the only stretchable lead on the market. This ...
Breaking Medicine News(10 mins):